graviti itacitinib miss weigh share pt
itacitinib fail reach statist signific primari endpoint day orr
pivot studi pivot studi itacitinib plu
steroid vs steroid alon patient treatment naiv acut gvhd itacitinib
improv day orr vs steroid alon vs numer
differ statist signific benefit key
secondari endpoint six-month non-relaps mortal updat model
po itacitinib drive pt prior maintain
outperform rate look forward catalyst includ studi result
rux cream atop dermat
studi itacitinib corticosteroid vs placebo
corticosteroid treatment-nav agvhd orr primari endpoint day
itacitinib arm vs placebo arm
statist signific benefit also non-relaps mortal nrm rate month
differ itacitinib placebo arm vs respect
itacitinib show numer trend toward benefit respons rate
fail cross threshold statist signific miss like due
unexpectedli high respons rate placebo corticosteroid arm
publish literatur point rang respons treatment-nav agvhd
patient popul treat corticosteroid like respons rate slightli
safeti profil itacitinib consist previou
studi itacitinib common thrombocytopenia
itacitinib placebo anemia itacitinib
think studi result agvhd
necessarili read across result itacitinib
studi cgvhd set decreas po itacitinib
model conserv purpos receiv result
studi itacitinib contribut per share model
hypothet sotp analysi includ jakafi
topic ruxolitinib respect intern pipelin asset includ pemigatinib
parasaclisib extern pipelin asset invest cash respect
contribut reduc pt prior due
itacitinib failur retain outperform thesi exhibit
year price histori incyt
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
jakafi success commerci gvhd
topic ruxolotinib approv dermatolog condit
accret invest cash rel low-risk pipelin asset
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig partner candid baricitinib oral
therapi ra may drive revenu upsid eventu
deep promis pipelin includ capmatinib
divers pipelin drive acceler revenu
growth current under-valu view
gvhd result
potenti fda approv pemagatinib
catmatinib nda file partner
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could
peak us includ peak royalti ex-u sale see iclusig olumi smaller contributor
revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit jakafi topic ruxolitinib contribut per share respect
intern pipelin asset pemigatinib parasaclisib extern pipelin asset invest
cash contribut per share respect sotp analysi
exhibit pt support dcf valuat
drug/indicationexpect launchpeak sale estim mm estimate probabl successnpv mm p-adj npv mm p-adj valu sharejakafi pipelin asset fgfr pipelin asset invest equiti share outstand use valuat oppenheim co discount analysisoppenheim co except per-shar data revenu chang work work capit valu growth valu oppenheim co estimatesequ valu per sharetermin valu growth rate
thousand except per share
product royalti revenu olumi us eu row
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
probabl success
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
share-bas compens cog
share-bas compens expens
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
amort acquir product right
chang fair valu equiti invest
non-cash interest expens relat convert note
expens relat senior note convers
tax effect non-gaap adjust
ep basic dilut
ep non-gaap basic dilut
share use comput ep dilut
fulli dilut share out use valuat
